GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » American Cryostem Corp (OTCPK:CRYO) » Definitions » Net Current Asset Value

American Cryostem (American Cryostem) Net Current Asset Value : $-0.06 (As of Jun. 2022)


View and export this data going back to 2010. Start your Free Trial

What is American Cryostem Net Current Asset Value?

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

American Cryostem's net current asset value per share for the quarter that ended in Jun. 2022 was $-0.06.

The historical rank and industry rank for American Cryostem's Net Current Asset Value or its related term are showing as below:

CRYO's Price-to-Net-Current-Asset-Value is not ranked *
in the Biotechnology industry.
Industry Median: 3.84
* Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.

American Cryostem Net Current Asset Value Historical Data

The historical data trend for American Cryostem's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

American Cryostem Net Current Asset Value Chart

American Cryostem Annual Data
Trend Sep12 Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21
Net Current Asset Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.03 -0.03 -0.04 -0.02 -0.04

American Cryostem Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
Net Current Asset Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.02 -0.04 -0.05 -0.06 -0.06

Competitive Comparison of American Cryostem's Net Current Asset Value

For the Biotechnology subindustry, American Cryostem's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


American Cryostem's Price-to-Net-Current-Asset-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, American Cryostem's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where American Cryostem's Price-to-Net-Current-Asset-Value falls into.



American Cryostem Net Current Asset Value Calculation

American Cryostem's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Sep. 2021 is calculated as

Net Current Asset Value Per Share(A: Sep. 2021 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(0.197-2.904-0-0)/61.3745
=-0.04

American Cryostem's Net Current Asset Value (NCAV) per share for the quarter that ended in Jun. 2022 is calculated as

Net Current Asset Value Per Share(Q: Jun. 2022 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(0.115-2.935-0-0)/44.1819
=-0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


American Cryostem  (OTCPK:CRYO) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


American Cryostem Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of American Cryostem's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.


American Cryostem (American Cryostem) Business Description

Traded in Other Exchanges
N/A
Address
1 Meridian Road, Suite 5, Eatontown, NJ, USA, 07724
American Cryostem Corp is a biotechnology company which standardizes adipose tissue-derived technologies (Adult Stem Cells) for the fields of Regenerative and Personalized Medicine. The company acts as an innovator of adipose tissue and stem cell platform technologies. It provides the clinical grade, adipose tissue and adult stem cell collection, processing, and cryo-preservation technology, providing first-in-class cellular therapy products and services for patients, physicians and researchers based on the transformative science of Regenerative and Personalized Medicine.
Executives
John S Arnone director, officer: Chairman 111 GREAT NECK RD, GREAT NECK NY 11021
Anthony Francis Dudzinski director, officer: COO 188 EAST BERGEN PLACE, SUITE 204, RED BANK NJ 07701
Acs Global, Inc. 10 percent owner 188 E. BERGEN PLACE, SUITE 204, RED BANK NJ 07701
Christopher Joseph Neill 10 percent owner 188 EAST BERGEN PLACE, SUITE 204, RED BANK NJ 07701
Hector Medina director, 10 percent owner, officer: President and Director 1206 STAGECOACH TRAIL LOOP, CHULA VISTA CA 91915